Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Braz. oral res. (Online) ; 33: e086, 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1019605

RESUMO

Abstract Treatment of patients with bisphosphonate usage is a significant concern for oral surgeons because it interferes with jaw bone turnover and regeneration. In case of adverse effects manifesting related to bisphosphonate use, oral surgeons are usually treating and keep the patient's symptoms under control. In this study, we aimed to investigate a new treatment protocol for medication-related osteonecrosis of the jaw (MRONJ). This treatment protocol consisted of administering human parathyroid hormone (hPTH) loaded chitosan microspheres which were prepared by ionotropic gelation method or/and the prepared microspheres were suspended in a poloxamer gel. After in-vitro optimization studies, the efficacy of the chosen formulations was evaluated in-vivo studies. Zoledronic acid was administered daily to forty-eight adult female Sprague-Dawley rats, divided into four experimental groups, at a daily concentration of 0.11 mg/kg over three weeks to induce the MRONJ model. At the end of this period, maxillary left molar teeth were extracted. In the first group, the subjects received no treatment. In the negative control group, poloxamer hydrogel containing empty microspheres were immediately applied to the soft tissues surrounding the extraction socket. The treatment group-1 was treated with local injections of poloxamer hydrogel containing hPTH. The treatment group-2 was treated with a single local injection of poloxamer hydrogel containing hPTH-loaded chitosan microspheres. Both treatment groups received a total of 7 µg of hPTH at the end of the treatment protocol. Our study demonstrates successful attenuation of MRONJ through a local drug delivery system combined with hPTH, as opposed to previously attempted treatment strategies.


Assuntos
Humanos , Animais , Feminino , Hormônio Paratireóideo/farmacologia , Quitosana/farmacologia , Conservadores da Densidade Óssea/farmacologia , Maxila/efeitos dos fármacos , Hormônio Paratireóideo/uso terapêutico , Ratos Sprague-Dawley , Poloxâmero/administração & dosagem , Poloxâmero/química , Modelos Animais , Preparações de Ação Retardada , Quitosana/uso terapêutico , Conservadores da Densidade Óssea/efeitos adversos , Conservadores da Densidade Óssea/uso terapêutico , Osteonecrose da Arcada Osseodentária Associada a Difosfonatos , Osteonecrose da Arcada Osseodentária Associada a Difosfonatos/tratamento farmacológico , Ácido Zoledrônico/efeitos adversos , Maxila/patologia , Microesferas
2.
J. appl. oral sci ; 24(3): 239-249, tab, graf
Artigo em Inglês | LILACS, BBO | ID: lil-787550

RESUMO

ABSTRACT Diabetes mellitus (DM) causes an increased production of free radicals that can impair bone healing. Melatonin is a hormone secreted mainly by the pineal gland, which participates in the neutralization process of free radicals. Objective The aim of this study was to investigate histologic and biochemical effects of supplemental melatonin administration on bone healing and antioxidant defense mechanism in diabetic rats. Material and Methods Eighty-six Sprague-Dawley male rats were used in this study. Diabetes mellitus was induced by intraperitoneal (i.p.) administration of 65 mg/kg streptozotocin (STZ). Surgical bone defects were prepared in the tibia of each animal. Diabetic animals and those in control groups were treated either with daily melatonin (250 μg/animal/day/i.p.) diluted in ethanol, only ethanol, or sterile saline solution. Rats were humanely killed at the 10th and 30th postoperative days. Plasma levels of Advanced Oxidation Protein Products (AOPP), Malondialdehyde (MDA), and Superoxide Dismutase (SOD) were measured. The number of osteoblasts, blood vessels and the area of new mineralized tissue formation were calculated in histologic sections. Results At the 10th day, DM+MEL (rats receiving both STZ and melatonin) group had significantly higher number of osteoblasts and blood vessels as well as larger new mineralized tissue surfaces (p<0.05 for each) when compared with DM group. At the 30th day, DM group treated with melatonin had significantly lower levels of AOPP and MDA than those of DM group (p<0.05). Conclusion Melatonin administration in STZ induced diabetic rats reduced oxidative stress related biomarkers and showed beneficial effects on bone healing at short term.


Assuntos
Animais , Masculino , Sequestradores de Radicais Livres/administração & dosagem , Consolidação da Fratura/efeitos dos fármacos , Diabetes Mellitus Experimental/metabolismo , Melatonina/administração & dosagem , Osteoblastos/efeitos dos fármacos , Valores de Referência , Superóxido Dismutase/sangue , Tíbia/efeitos dos fármacos , Tíbia/patologia , Fatores de Tempo , Fibrose , Calcificação Fisiológica/efeitos dos fármacos , Biomarcadores , Contagem de Células , Reprodutibilidade dos Testes , Ratos Sprague-Dawley , Estreptozocina , Estresse Oxidativo/efeitos dos fármacos , Diabetes Mellitus Experimental/induzido quimicamente , Produtos da Oxidação Avançada de Proteínas/sangue , Malondialdeído/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA